Agenda

6/4/02


Click here to start


Table of Contents

Agenda

Safety Overview

Safety Database

Comparison of Placebo vs. Alefacept Experience

Safety Overview Placebo-Controlled Studies

Safety Overview by Course

Adverse Events ?5% Incidence Placebo-Controlled Studies

Serious Adverse Events

Most Frequent Serious Adverse Events*

Most Frequent Serious Adverse Events*

Deaths

Deaths

Infections

Infections ?5% Incidence

Infections by CD4+ T Cell Counts*

Serious Infections

Serious Skin Infections - All Studies

Infection: Conclusions

Functional Integrity of Immune System

Malignancy

Incidence of Malignancies

Incidence of Malignancies

Single case of B cell lymphoma

Overall Malignancy Rates

Malignancy Conclusions

Percentage Testing Positive for Anti-Alefacept Antibodies

Safety Conclusions

Plans for Extended Long-Term Safety Evaluation

Alefacept Conclusions

Agenda

Author: Steven Ertel